The use of etoposide for covid-19 treatment

Mooij, Salomé (2021) The use of etoposide for covid-19 treatment. Research Project, Pharmacy.

Preview	Text Capita Farmacia Salomé Mooij S3051579.pdf Download (372kB) | Preview
	Text toestemming.pdf Restricted to Registered users only Download (134kB)

Abstract

SARS-CoV-2, or Covid-19, has been classified as a Public Health Emergency of International Concern by the World Health Organisation (WHO (1)). Although vaccines are currently being administered, there is still no effective treatment for Covid-19. Because of this, there is a lot of interest for potentially effective Covid-19 therapeutics. One of these therapeutic agents is etoposide. Etoposide gained interest as a potential Covid-19 therapeutic after it had been established that the severe phase of Covid-19 resembles the disease course of hemophagocytic lymphohistiocytosis (HLH). Etoposide is a chemotherapeutic agent that is also used as the standard therapy against HLH. Both in HLH and in severe Covid-19, there is an excessive response of the immune system, leading to activation of T-cells and macrophages, eventually leading to excessive release of cytokines. This cytokine storm causes multi-organ damage, which can be fatal (2) (3). In this essay, the background of Covid-19 and etoposide is discussed and the available clinical data on etoposide as a treatment against Covid-19 is analysed. As clinical data on the use of etoposide against Covid-19 is limited, prospects of etoposide as a Covid-19 therapeutic are difficult to determine. However, based on case reports and available literature on the use of etoposide against Covid-19, etoposide has potential as a therapeutic agent against Covid-19.

Item Type:	Thesis (Research Project)
Supervisor name:	Haslinger, K. and Quax, W.J.
Degree programme:	Pharmacy
Thesis type:	Research Project
Language:	English
Date Deposited:	14 Jul 2021 08:20
Last Modified:	14 Jul 2021 08:20
URI:	https://fse.studenttheses.ub.rug.nl/id/eprint/25227

Actions (login required)

View Item